Future Trends in Peptide Research: What's Next After GH?

From growth hormone to narrower targets

For about two decades, the peptides most lifters talked about did one job: raise growth hormone. Ipamorelin and CJC-1295 both push the pituitary to release more of it, through different receptors. Small human studies confirm they raise growth hormone and IGF-1, but not that they improve strength or performance.

The longest controlled data come from MK-677, an oral ghrelin mimetic rather than an injected peptide. In a two-year randomized trial in 65 healthy adults aged 60 to 81, it raised growth hormone and IGF-1 to young-adult levels and added about 1.1 kg of fat-free mass over the first year. Strength and function didn't change. Fasting blood glucose rose and insulin sensitivity fell. Users of the injectable secretagogues commonly describe water retention and tingling hands. Raising growth hormone across the whole body brings side effects along with the effect people want.

Our guide to how CJC-1295 and ipamorelin work covers that mechanism. Much of the newer research aims at narrower targets, often a single organ or disease, and our overview of the clinical peptide data explains how to weigh the study types below.

Oral peptides: approved for obesity, not for performance

Injections are the most common practical complaint about peptides, so a lot of development work goes into pills. The obstacle is chemistry: stomach acid and digestive enzymes break most peptides down before they're absorbed.

As of October 2026, the clearest success is oral semaglutide. FDA approved the Wegovy pill for weight management on December 22, 2025. In the OASIS 4 trial, people on the top tablet dose lost an average of 16.6% of body weight at 64 weeks if they kept taking it, according to CNBC's summary of the results.

The pill depends on an absorption enhancer called SNAC. A 2018 study in Science Translational Medicine found that oral semaglutide is absorbed in the stomach, right next to the dissolving tablet, and only when SNAC is in the same tablet. SNAC buffers the acid locally, protecting the peptide from enzymes. The authors called the mechanism compound-specific, so it can't simply be copied onto other peptides. Even so, people taking the pill have to wait 30 minutes before eating or drinking, CNBC reports.

Lilly took another route. Its pill Foundayo (orforglipron), approved on April 1, 2026, acts on the same GLP-1 receptor but is a small molecule rather than a peptide, and FDA notes it doesn't need an empty stomach. Some oral peptide programs may end up replaced by small molecules rather than reformulated.

None of this has reached the peptides lifters usually buy. As of October 2026, we found no trial of an oral SNAC-style version of BPC-157 or any growth hormone secretagogue. BPC-157 is often sold in oral form because animal studies describe it as stable in gastric juice, but we found no human data on how much of an oral dose is absorbed.

Metabolic peptides that act on several receptors

Metabolic research is also moving toward single peptides that act on more than one hormone receptor. Retatrutide is a triple agonist: it acts on the GLP-1 and GIP receptors plus the glucagon receptor. As of October 2026, Lilly reports five positive Phase 3 trials. In TRIUMPH-3, adults with severe obesity and cardiovascular disease lost up to 22.6% of body weight at 80 weeks. Dysesthesia (abnormal burning or tingling of the skin) affected 4.5% to 7.3% of people on retatrutide in TRIUMPH-2, compared with 0.7% on placebo.

Retatrutide isn't approved anywhere; Lilly plans to file with FDA in the first quarter of 2027. Vials sold online under that name aren't the trial drug. Our fat-loss peptides overview compares it with the approved GLP-1 drugs.

Mitochondrial and muscle drugs reach approval

In September 2025, FDA granted accelerated approval to elamipretide (Forzinity), the peptide sold online as SS-31, for Barth syndrome, a rare mitochondrial disease. The approval rests on improved knee-extension strength, which FDA considers reasonably likely to predict real benefit, and a confirmatory placebo-controlled trial is required. Elamipretide remains investigational for other conditions, which our mitochondrial peptides hub covers.

The myostatin pathway has its first approval too. As of October 2026, FDA has approved apitegromab (Isembyld) for spinal muscular atrophy. It's an antibody rather than a peptide, approved to address muscle loss in a genetic disease, not to build muscle in healthy people. In its 52-week trial, children aged 2 to 12 on the drug were more than twice as likely as those on placebo to show a meaningful motor improvement (34.2% vs 13.5%). FDA reports an increased risk of fractures.

Bioregulators and the Khavinson hypothesis

Bioregulators are very short peptides, often two to four amino acids long, studied mostly by Vladimir Khavinson's group in St. Petersburg. Their hypothesis is that these peptides enter cells and adjust gene expression directly. Nearly all of the testing has come from the same research network.

Epitalon (also spelled epithalon) is the best known. In its July 2026 advisory committee briefing, FDA found three human studies of epitalon. Two gave it under the tongue to night-shift workers and measured circadian genes or a melatonin breakdown product; the third injected it near the eye in people with retinitis pigmentosa. Claims that epitalon lengthens telomeres come from cell cultures, where Khavinson's group reported higher telomerase activity. FDA also treats epitalon as a different substance from epithalamin, the pineal gland extract it was modeled on.

That matters for the most-cited result. A 2003 paper from the group followed 266 older adults for six to eight years and reported lower death rates in people given Thymalin or Epithalamin (thymus and pineal extracts, not synthetic epitalon). The abstract doesn't say how people were assigned to groups or whether anyone was blinded. This site rates epitalon's evidence as emerging.

Brain-targeted peptides

Semax and Selank, both developed in Russia, have more human use behind them than most research peptides. The trials are small and mostly lack a placebo group, though.

• Semax is a modified fragment of ACTH (adrenocorticotropic hormone). In a 1997 Russian study, 30 stroke patients given Semax with standard care were compared with 80 on standard care alone; the authors reported faster recovery of some neurological functions. In July 2026, FDA reviewers found insufficient evidence of effectiveness for migraine or trigeminal neuralgia.
• Selank is related to tuftsin, an immune peptide. In a 2008 study of 62 patients with generalized anxiety disorder or neurasthenia, Selank and the benzodiazepine medazepam had similar anti-anxiety effects, with no placebo arm.

Users on nootropic forums commonly describe sharper focus with Semax and a calmer mood with Selank, while some report headaches or poor sleep. We found no placebo-controlled trial of either for focus or mood in healthy people.

Dihexa is a different case. Washington State University researchers designed it as a stable angiotensin IV analog, and a 2013 paper reported better maze performance and more new synapses in rats. A 2014 paper from the same lab tied those effects to hepatocyte growth factor (HGF) and its c-Met receptor. The journal retracted it in 2025 after a university investigation found falsified or fabricated data, along with a related 2012 paper. The 2013 paper received an expression of concern in 2021 over possible image manipulation.

The often-repeated claim that dihexa is millions of times more potent than BDNF describes a lab-dish assay; we couldn't confirm which paper it comes from. As of October 2026, we found no human trial of dihexa itself. The nearest human data come from fosgonimeton, a related compound from Athira Pharma, a company spun off from the same lab's work. Its Phase 2/3 LIFT-AD trial in Alzheimer's disease missed its primary and secondary endpoints. This site rates dihexa's evidence as preliminary.

How the classes compare

For the recovery peptides, the movement right now is mostly regulatory. Our BPC-157 and TB-500 comparison covers the animal studies and where the human data stop.

What to watch next

• FDA rulemaking on peptides its advisers backed. In July 2026, FDA's compounding advisory committee recommended six peptides for the 503A bulks list, including semax and epitalon. According to the FDA Law Blog, a proposed rule will settle the question; as of October 2026, FDA hasn't published one. Our legal status overview tracks it.
• A placebo-controlled BPC-157 trial, a University of Arkansas pilot of about 30 patients after rotator cuff surgery, listed in October 2026 as not yet recruiting.
• Retatrutide's US filing, planned for early 2027.
• Elamipretide's confirmatory trial, which will decide whether its approval holds.
• Independent replication of the bioregulator and dihexa findings outside the original labs.